Quarterly Financial Data

12 Months Ended

Dec. 28, 2013

Quarterly Financial Data [Abstract]

Quarterly Financial Information [Text Block]

QUARTERLY FINANCIAL DATA (UNAUDITED)

	First			Second			Third			Fourth
(in millions, except per share amounts)	Quarter			Quarter			Quarter			Quarter
Fiscal Year 2013:
Net sales	$	1,338		$	1,403		$	1,338		$	1,422
Gross profit	961			1,021			953			992
Net earnings attributable to St. Jude Medical, Inc. (a)	223		(b)	115		(c)	262		(d)	123		(e)
Basic net earnings per share	$	0.78		$	0.41		$	0.91		$	0.42
Diluted net earnings per share	$	0.78		$	0.40		$	0.90		$	0.42
Cash dividends declared per share	$	0.25		$	0.25		$	0.25		$	0.25
Fiscal Year 2012:
Net sales	$	1,395		$	1,410		$	1,326		$	1,372
Gross profit	1,014			1,027			971			953
Net earnings attributable to St. Jude Medical, Inc. (f)	212		(g)	244			176		(h)	120		(i)
Basic net earnings per share	$	0.67		$	0.78		$	0.56		$	0.39
Diluted net earnings per share	$	0.67		$	0.78		$	0.56		$	0.39
Cash dividends declared per share	$	0.23		$	0.23		$	0.23		$	0.23

(a) Restructuring and realignment activities related to previously announced actions as the Company continues to integrate its product divisions and centralize certain support functions resulted in after-tax special charges of $32 million for the first quarter, $34 million for the second quarter, $13 million for the third quarter and $97 million for the fourth quarter of 2013.

(b) Includes after-tax acquisition-related charges of $29 million to adjust the carrying value of the Company's pre-existing CardioMEMS equity investment and fixed price purchase option to fair value and a $21 million income tax benefit related to extending the 2012 federal research and development tax credit, retroactive to the beginning of our 2012 tax year.

(c) Includes $101 million of after-tax debt retirement costs primarily associated with the make-whole redemption payments and the write-off of unamortized debt issuance costs, $14 million of after-tax special charges related to a license dispute settlement charge, $8 million related to after-tax special charges associated with intangible asset impairment charges and $3 million of after-tax acquisition-related costs.

(d) Includes a $15 million income tax benefit related to the settlement of domestic tax audits and $2 million of after-tax charges associated with acquisition-related costs.

(e) Includes $25 million of after-tax special charges associated with IESD litigation and field action costs, $19 million of after-tax special charges related to intangible asset impairment charges, $15 million of after-tax acquisition-related costs and a $15 million income tax expense charge related to prior year uncertain tax positions in foreign jurisdictions.

(f) Restructuring and realignment activities resulted in after-tax special charges of $29 million for the first quarter, $27 million for the second quarter, $66 million for the third quarter and $75 million for the fourth quarter of 2012.

(g) Includes after-tax special charges of $25 million related to a license dispute settlement charge.

(h) Includes after-tax special charges of $15 million for intangible asset impairment charges.

(i) Includes after-tax special charges of $27 million related to IESD litigation and field action costs and after-tax special charges of $11 million for intangible asset impairment charges and CATD inventory write-offs associated with discontinued product lines. Additionally, the Company recognized $46 million of additional income tax expense related to a settlement reserve for certain prior year tax positions.